During the coronavirus disease 2019 (COVID-19) pandemic, clinics have closed to varying degrees. As clinics look to reopen or welcome back patients after a COVID-19 infection, the American College of Rheumatology (ACR) has released advice on strategies for reopening practices as the pandemic continues.
When the coronavirus disease 2019 (COVID-19) first started spreading in the United States, rheumatologists and rheumatology health professionals reduced the number of face-to-face visits and other services to various degrees. Now, they are looking at phased reopenings, which may vary significantly depending on local conditions, according to the American College of Rheumatology (ACR).
As stay-at-home orders are revised and businesses in the United States begin to reopen, rheumatology practices are also returning to normal business, which has prompted ACR to release advice on strategies for reopening practices during the COVID-19 pandemic.
“The ACR holds that the individuals best suited to evaluate local conditions and coordinate reopening efforts are providers who, in shared decision making with their patients, staff and local authorities, can devise and follow plans to maximize patient safety and deliver high quality care,” the document said.
The document is split into 3 sections based on the main questions patients and staff might have:
Returning to the Workplace
ACR recommends advising patients to continue working from home if possible, avoid group interactions, wear a mask, and practice careful hand hygiene. The document notes that over time, factors influencing whether or not a patient can return to the workplace may evolve, depending on future therapeutic advances and the availability of a COVID-19 vaccine.
Individual circumstances should also be taken into account when advising patients whether or not they should return to the workplace. This may include:
Similar considerations should be taken when advising patients about returning to public spaces beyond work, including family visits. ACR recommends advising that patients also take into account the risk to those around them and if they could expose the elderly and those with comorbid conditions if they are infected.
Reopening the Clinic
The ACR document provides a long list of suggestions to be taken into account when reopening a medical facility. Among the suggestions are:
ACR is also recommending offices have a plan if a patient tests positive after visiting the clinic in case they were asymptomatic during the visit.
Returning After a Confirmed Case
In addition to when patients can return to the clinic after COVID-19 infection, there is also the question of when patients can safely resume disease-modifying antirheumatic drugs and/or biologic therapy after infection.
Data around when patients can resume treatment are lacking, ACR notes, but the organization has recommended previously that patients who had uncomplicated infections may restart treatments within 7 to 14 days after symptoms resolve. Patients who have a positive test but are asymptomatic may consider restarting treatments 10 to 17 days after the positive test. Patients who are recovering from more severe infections may need to be evaluated on a case-by-case basis.
Data about when people can return to the clinic after an infection are emerging. For now, ACR recommends that people can return when they have been without a fever for at least 24 hours, symptoms have improved, and at least 10 days have passed since the onset of their symptoms. Patients with severe or critical COVID-19 or who are severely immune compromised should wait 20 days from the onset of their symptoms. Asymptomatic patients who test positive may return 10 days after the positive test if they do not develop symptoms.
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Frameworks for Advancing Health Equity: LGBTQIA+ Affirming Provider Designation
July 9th 2024Kim Zynn, vice president of UPMC Health Plan's provider network and development relations team, shares how physicians can become LGBTQIA+ affirming providers, which is designated within the health plan.
Listen